Do tirzepatide and semaglutide help beyond weight loss?
Yes, for some. Semaglutide (Wegovy, Ozempic) reduced heart attacks, strokes and heart deaths, slowed diabetic kidney decline and improved a serious fatty-liver disease. Tirzepatide (Mounjaro, Zepbound) cut sleep apnoea breathing pauses by half or more, and the US Mounjaro label now lists heart protection in type 2 diabetes. Semaglutide did not slow Alzheimer's, and both often cause stomach upset.
Which benefits beyond weight loss are on the labels?
US labels list uses beyond weight and blood sugar: heart protection, kidney protection, sleep apnoea and a serious fatty-liver disease called MASH.1,2,3,20
- Heart (Wegovy). In SELECT, adults with heart disease and overweight but no diabetes took Wegovy or placebo for a median of about 3½ years. A heart attack, stroke or heart death happened in 6.5% on Wegovy, against 8.0% on placebo.1
- Heart (Mounjaro). In SURPASS-CVOT, 13,299 adults with type 2 diabetes and heart disease took Mounjaro or another GLP-1, Trulicity. Heart attacks, strokes and heart deaths were about as common on each. Mounjaro was not shown to be better.20
- Kidneys (Ozempic). In FLOW, 3,533 adults with type 2 diabetes and kidney disease took Ozempic 1 mg or placebo. Follow-up lasted a median of 41 months. Kidney function halving, kidney failure, or death from kidney or heart causes occurred in 18.7%, against 23.2%. The US Ozempic label also lists heart protection in adults with type 2 diabetes and heart disease.3
- Sleep apnoea (Zepbound). Two 52-week trials enrolled 469 adults with obesity and moderate to severe sleep apnoea. Breathing pauses per hour fell by 51% and 59% on Zepbound, against about 3% on placebo. Apnoea went into remission or became mild without daytime sleepiness in 42% and 50%, against 16% and 14%.2
- Liver (Wegovy injection). The trial enrolled 800 adults with MASH and moderate to advanced scarring. At 72 weeks, liver inflammation cleared without worse scarring in 63% on Wegovy, against 34% on placebo. Scarring improved in 37%, against 22%. This is an accelerated approval that still depends on a confirming trial.1
Which of these uses a label lists differs by country. Each country's position is under “In your country” below.
What do trials show for joint pain, alcohol and memory?
Trials found less knee pain and some drop in drinking on semaglutide, but semaglutide tablets did not slow early Alzheimer's.4,5,6
Knee pain. In STEP 9, 407 adults with obesity and knee osteoarthritis took Wegovy 2.4 mg or placebo for 68 weeks. Pain scores fell by 41.7 points, against 27.5, and weight fell by 13.7%, against 3.2%. More people stopped semaglutide for side effects, 6.7% against 3.0%. Novo Nordisk, which makes Wegovy, paid for the trial.4
Alcohol. A 9-week trial gave 48 adults with alcohol use disorder low-dose semaglutide or placebo. On semaglutide, people drank less on drinking days and reported less craving, but did not drink on fewer days.5 None of the US labels we read lists alcohol use disorder as a use.1,2,3,20
Alzheimer's disease. In the EVOKE trials, 3,808 adults with early Alzheimer's disease took semaglutide 14 mg tablets or placebo. At 2 years, scores for memory and daily function had worsened by about the same amount in both groups. Novo Nordisk paid for both trials.6
What do people on GLP-1 medicines report beyond weight loss?
From public patient forums: 583 Reddit threads in r/Zepbound, r/Mounjaro, r/mounjarouk, r/WegovyWeightLoss, r/Semaglutide and r/glp1, posted October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the trial Many describe joint, back or foot pain easing, though some saw no change. STEP 9 found less knee osteoarthritis pain on semaglutide than placebo; other joints were not tested.4
- Matches the label Several say snoring or sleep apnoea improved, while some still needed a breathing machine worn at night (CPAP). The US Zepbound label lists sleep apnoea in adults with obesity as a use.2
- Matches the trial Several say their blood pressure fell, and a few felt dizzy or fainted on blood pressure medicines. In the Zepbound sleep apnoea trials, blood pressure fell more than on placebo. The US label reports low blood pressure more often in people taking blood pressure medicines.1,2
- Matches the trial Several notice less desire for alcohol; a minority saw no effect. In a small trial, semaglutide reduced drinks on drinking days and craving.5
- Matches the label Several report fatty liver or liver tests improving. The US Wegovy label covers MASH with moderate to advanced scarring only.1
Advice people share
- Matches the label A few advise checking blood pressure at home and having blood pressure medicines reviewed as weight falls. The US labels report low blood pressure more often in people on these medicines.1,2
- Matches the label A few advise a repeat sleep study before giving up CPAP. The Canadian Zepbound label says it does not replace CPAP for people who need it.10
- Label says otherwise A few mention “microdosing” or staying below the starting dose. The US Zepbound label starts at 2.5 mg and says that dose is for starting treatment only, not for maintenance.2
- Stomach side effects such as nausea, diarrhoea, vomiting and constipation are the most common on the US Wegovy and Zepbound labels.1,2 In STEP 9, more people stopped semaglutide for side effects, 6.7% against 3.0%.4
- Low blood pressure affected 1.6% on Zepbound against 0.1% on placebo. It was more common in people already taking blood pressure medicines.2
- Inflamed pancreas (pancreatitis) is a labelled risk. Its sign is severe stomach pain that sometimes spreads to the back.1
- Thyroid tumours. The US labels carry a boxed warning about thyroid C-cell tumours seen in rodents. They say not to use these medicines with a personal or family history of medullary thyroid cancer or MEN 2.1,2
- Gallbladder problems, including gallstones, are a labelled risk. Kidney problems can follow dehydration from vomiting or diarrhoea.1,2
- Pregnancy. The US Wegovy label says to stop at least 2 months before a planned pregnancy. The US Zepbound label says to stop once a pregnancy is known.1,2
In your country
The trial results are the same everywhere. Whether a label lists heart, kidney, sleep apnoea or liver protection as a use differs by country.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian labels list sleep apnoea for Mounjaro and kidney disease in type 2 diabetes for Ozempic.8,9 The Australian Mounjaro label lists no heart use.8 Wegovy lists MASH under provisional approval, and its heart use is only for adults without diabetes.7
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The Canadian labels list the same sleep apnoea, kidney and MASH uses as the US ones.10,11,12 The Wegovy heart use is narrower, covering only the risk of a non-fatal heart attack.11 The Canadian Mounjaro label lists blood sugar control only, with no heart use.21
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU labels list weight and type 2 diabetes as uses. They describe the heart, kidney and sleep apnoea trials, including Mounjaro's heart trial, but do not list them as uses. The EU Wegovy label has no MASH use.13,14,15
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU labels list weight and type 2 diabetes as uses. They describe the heart, kidney and sleep apnoea trials, including Mounjaro's heart trial, but do not list them as uses. The EU Wegovy label has no MASH use.13,14,15
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label, so this page relies on the US and EU labels.
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label, so this page relies on the US and EU labels.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label, so this page relies on the US and EU labels.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Wegovy label lists the heart and MASH uses.16 The UK Mounjaro label describes the heart and sleep apnoea trials but does not list them as uses.17 The UK Ozempic label does the same for the kidney trial.18
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, sometimes spreading to your back, or nausea, vomiting or diarrhoea that does not stop.1
Read the full picture
Related questions
Sources
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, boxed warning and sections 1, 5, 6, 8, 14.1 (SELECT, Table 6), 14.4 (MASH, Table 21) and 17 (US label). DailyMed
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, boxed warning and sections 1, 2.1, 5, 6, 8 and 14.2 (sleep apnoea trials, Table 9) (US label). PDF
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, sections 1 and 14 (FLOW, Table 10) (US label). DailyMed
- Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med 2024;391:1573–83. Funded by Novo Nordisk. DOI · PMID 39476339
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. DOI · PMID 39937469
- Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+). Lancet 2026;407:2167–79. Funded by Novo Nordisk. DOI · PMID 41865758
- Novo Nordisk. Wegovy (semaglutide) Australian Product Information, section 4.1 (Australian label). medsinfo.com.au
- Eli Lilly. Mounjaro (tirzepatide) Australian Product Information, section 4.1 (Australian label). PDF
- Novo Nordisk. Ozempic (semaglutide) Australian Product Information, section 4.1 (Australian label). PDF
- Eli Lilly Canada. Zepbound (tirzepatide injection) Product Monograph, sections 1 and 4.1 (Canadian label). PDF
- Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, section 1 (Canadian label). PDF
- Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, section 1 (Canadian label). PDF
- European Medicines Agency. Wegovy: EU summary of product characteristics, section 4.1 (EU label). PDF
- European Medicines Agency. Mounjaro: EU summary of product characteristics, sections 4.1 and 5.1 (SURPASS-CVOT) (EU label). PDF
- European Medicines Agency. Ozempic: EU summary of product characteristics, section 4.1 (EU label). PDF
- Novo Nordisk. Wegovy 2.4 mg FlexTouch: UK summary of product characteristics, section 4.1 (UK label). emc
- Eli Lilly. Mounjaro KwikPen: UK summary of product characteristics, sections 4.1 and 5.1 (SURPASS-CVOT) (UK label). emc
- Novo Nordisk. Ozempic 1 mg: UK summary of product characteristics, section 4.1 (UK label). emc
- American College of Emergency Physicians. Emergency physicians explain how to recognize signs of a heart attack. 20 February 2026. Link
- Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 08/2026, sections 1 and 14.6 (SURPASS-CVOT, Table 10) (US label). PDF
- Eli Lilly Canada. Mounjaro (tirzepatide injection) Product Monograph, section 1 (Canadian label). PDF
Last checked 16 Nov 2026 · Next review due 16 Nov 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between 9 and 16 Nov 2026. Trial rates come from the US labels and the trial papers. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write